Why is AGMB down?
Down 57% in 3 months, 37% under its 50-day average.
- Down more than its industry:
−2Volatility
1 more thing pulling AGMB's score down, for Pro members.
Down 57% in 3 months, 37% under its 50-day average.
−2Volatility
1 more thing pulling AGMB's score down, for Pro members.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | Moves 13.8% a day with no recent filing behind it |
| Latest filing | 6-K, Oct 13 |
Sat Feb 6: One year since its IPOListed Feb 6, 2026 at $16.
AGMB is #84 of 273 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 84 |
RSI 23.0, MACD below signal, below both averages. Not scored.
3 insiders bought $620K across 18 filings in the last 6 months. No open-market sales on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
Listed on Nasdaq on Feb 6, 2026, and is 66% below its $16 offer price now. Its IPO filing and first days
AGMB scores 2 today, which Breakaway calls Below Average. It is #84 of 273 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 57% in 3 months, 37% under its 50-day average. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
AGMB scores 2 today, which Breakaway calls Below Average (0 to 5). That is #84 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind AGMB's 2.
3 insiders bought $620K across 18 filings in the last 6 months. No open-market sales on record. The newest is David R. Epstein, Director, who bought $28K on Nov 17. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.